DE69814177T2 - Impfstoffe mit einem ltb adjuvans - Google Patents

Impfstoffe mit einem ltb adjuvans Download PDF

Info

Publication number
DE69814177T2
DE69814177T2 DE69814177T DE69814177T DE69814177T2 DE 69814177 T2 DE69814177 T2 DE 69814177T2 DE 69814177 T DE69814177 T DE 69814177T DE 69814177 T DE69814177 T DE 69814177T DE 69814177 T2 DE69814177 T2 DE 69814177T2
Authority
DE
Germany
Prior art keywords
vaccine
ltb
immunogen
subunit
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69814177T
Other languages
German (de)
English (en)
Other versions
DE69814177D1 (de
Inventor
Etienne Agsteribbe
Rudi Brands
Lolke De Haan
Johan Gustaaf VAN SCHARRENBURG
Ronald Willem VERWEIJ
Christiaan Jan WILSCHUT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Van Groningen Nl
Abbott Biologicals BV
Original Assignee
University of Groningen
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Groningen, Duphar International Research BV filed Critical University of Groningen
Application granted granted Critical
Publication of DE69814177D1 publication Critical patent/DE69814177D1/de
Publication of DE69814177T2 publication Critical patent/DE69814177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69814177T 1997-11-25 1998-11-24 Impfstoffe mit einem ltb adjuvans Expired - Lifetime DE69814177T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97203671 1997-11-25
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
PCT/EP1998/007553 WO1999026654A1 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant

Publications (2)

Publication Number Publication Date
DE69814177D1 DE69814177D1 (de) 2003-06-05
DE69814177T2 true DE69814177T2 (de) 2004-04-08

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814177T Expired - Lifetime DE69814177T2 (de) 1997-11-25 1998-11-24 Impfstoffe mit einem ltb adjuvans

Country Status (24)

Country Link
US (1) US6793928B1 (enExample)
EP (2) EP0919243A1 (enExample)
JP (1) JP4235359B2 (enExample)
KR (1) KR100575019B1 (enExample)
CN (1) CN1227032C (enExample)
AT (1) ATE238809T1 (enExample)
AU (1) AU747061C (enExample)
BR (1) BR9815413A (enExample)
CA (1) CA2311492C (enExample)
CZ (1) CZ299770B6 (enExample)
DE (1) DE69814177T2 (enExample)
DK (1) DK1071456T3 (enExample)
ES (1) ES2198089T3 (enExample)
HU (1) HU226214B1 (enExample)
IL (2) IL135905A0 (enExample)
NO (1) NO324690B1 (enExample)
NZ (1) NZ504396A (enExample)
PL (1) PL190925B1 (enExample)
PT (1) PT1071456E (enExample)
RU (1) RU2211050C2 (enExample)
SK (1) SK284572B6 (enExample)
TR (1) TR200001485T2 (enExample)
UA (1) UA72199C2 (enExample)
WO (1) WO1999026654A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
KR20010043441A (ko) 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
EP1075274A2 (en) * 1998-05-08 2001-02-14 University Of Bristol Immunomodulators for vaccines
EP1221970B1 (en) * 1999-10-18 2014-02-19 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stimulating an immune response against infectious agents
RU2223783C1 (ru) * 2002-07-05 2004-02-20 Российская медицинская академия последипломного образования Способ профилактики гриппа и острых респираторных заболеваний у часто болеющих детей
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
EP1708744A4 (en) * 2003-12-09 2009-07-15 Intercell Usa Inc GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
CN101522706B (zh) 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CN104379170B (zh) * 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
CN106170551B (zh) 2013-12-16 2020-01-07 财团法人农业科技研究院 生产不耐热肠毒素b亚单位的质粒、方法及其套组
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
CN111344397A (zh) * 2017-11-01 2020-06-26 默沙东公司 巨细胞病毒的稳定制剂
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3768302B1 (en) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2020227263A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
EP3975999A4 (en) 2019-06-03 2023-07-19 Theriva Biologics, Inc. ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
CN113616783B (zh) * 2020-05-08 2025-08-08 昱厚生技股份有限公司 使用免疫调节剂和包含所述免疫调节剂的疫苗组合物预防或治疗冠状病毒感染的方法
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
TWI896302B (zh) * 2024-08-22 2025-09-01 國立清華大學 重組蛋白及其製備方法、包含重組蛋白的疫苗蛋白質佐劑及重組蛋白用於預防呼吸道疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (enExample) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
AU4754490A (en) * 1988-12-07 1990-06-26 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
CN1280504A (zh) 2001-01-17
NO324690B1 (no) 2007-12-03
CZ20001895A3 (cs) 2000-10-11
DK1071456T3 (da) 2003-06-02
SK7762000A3 (en) 2000-11-07
PT1071456E (pt) 2003-09-30
PL190925B1 (pl) 2006-02-28
HK1031102A1 (en) 2001-06-01
JP2001523729A (ja) 2001-11-27
CZ299770B6 (cs) 2008-11-19
AU747061B2 (en) 2002-05-09
EP1071456A1 (en) 2001-01-31
BR9815413A (pt) 2000-10-17
AU747061C (en) 2005-02-24
EP0919243A1 (en) 1999-06-02
CA2311492C (en) 2011-10-18
US6793928B1 (en) 2004-09-21
HUP0100058A1 (hu) 2001-05-28
HUP0100058A3 (en) 2003-03-28
NO20002613D0 (no) 2000-05-22
IL135905A (en) 2006-08-01
ES2198089T3 (es) 2004-01-16
CN1227032C (zh) 2005-11-16
IL135905A0 (en) 2001-05-20
JP4235359B2 (ja) 2009-03-11
KR20010032425A (ko) 2001-04-16
ATE238809T1 (de) 2003-05-15
TR200001485T2 (tr) 2001-12-21
RU2211050C2 (ru) 2003-08-27
NZ504396A (en) 2002-09-27
CA2311492A1 (en) 1999-06-03
EP1071456B1 (en) 2003-05-02
WO1999026654A1 (en) 1999-06-03
NO20002613L (no) 2000-05-22
KR100575019B1 (ko) 2006-05-02
PL340635A1 (en) 2001-02-12
HU226214B1 (en) 2008-06-30
DE69814177D1 (de) 2003-06-05
AU1875099A (en) 1999-06-15
UA72199C2 (en) 2005-02-15
SK284572B6 (sk) 2005-06-02

Similar Documents

Publication Publication Date Title
DE69937571T2 (de) Mutiertes cholera holotoxin als hilfsmittel
KR100575019B1 (ko) Ｌｔｂ 면역보강제를 갖는 백신
DE69534992T2 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE69831594T2 (de) Intakte oder zerstörte insektenzellen als antigenadjuvant
EP1144001B1 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE60110822T2 (de) Zubereitung zur immunisierung gegen den aids-virus
DE69334066T2 (de) Impfstoffzusammensetzungen für mukosale Abgabe
DE69435075T2 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DE69421939T2 (de) Nichttoxisches schleimhautadjuvans
DE69532588T2 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
WO2008077527A1 (de) Rsv f-protein und seine verwendung
DE69110997T2 (de) Haemophilus Paragallinarum-Impfstoffe.
DE69434000T2 (de) Impfstoffzusammensetzungen
EP0833923B1 (de) Immunogenes konstrukt, verfahren zu dessen herstellung und verwendung als vakzine
KR100649286B1 (ko) 감독화톡신을 포함하는 백신제제
DE69428984T2 (de) Stimulierung der immunantwort durch virales protein
DE68908414T2 (de) Pharmazeutische zusammensetzungen für die reizung eines immunostimulierenden effektes.
DE69609739T2 (de) Pertussistoxin enthaltender Influenzaimpfstoff
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE60037413T2 (de) Rekombinante adhesin-proteine aus haemophilus influenzae
DE60216958T2 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
DE10351471A1 (de) Polyvalente Allergievakzine
MXPA00005127A (en) Vaccines with an ltb adjuvant

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SOLVAY BIOLOGICALS B.V., WEESP, NL

Owner name: UNIVERSITEIT VAN GRONINGEN, GRONINGEN, NL

R082 Change of representative

Ref document number: 1071456

Country of ref document: EP

Representative=s name: PRUEFER & PARTNER GBR, DE

R081 Change of applicant/patentee

Ref document number: 1071456

Country of ref document: EP

Owner name: UNIVERSITEIT VAN GRONINGEN, NL

Free format text: FORMER OWNER: SOLVAY BIOLOGICALS B.V., UNIVERSITEIT VAN GRONINGEN, , NL

Effective date: 20121116

Ref document number: 1071456

Country of ref document: EP

Owner name: ABBOTT BIOLOGICALS B.V., NL

Free format text: FORMER OWNER: SOLVAY BIOLOGICALS B.V., UNIVERSITEIT VAN GRONINGEN, , NL

Effective date: 20121116

R082 Change of representative

Ref document number: 1071456

Country of ref document: EP

Representative=s name: PRUEFER & PARTNER GBR, DE

Effective date: 20121116